FDA Approves Obesity Drug for Adolescents
Qsymia is only available through a Risk Evaluation and Mitigation Strategy (REMS) program because of the increased risk for birth defects.
The FDA has approved a supplemental indication for Vivus’s Qsymia (phentermine and topiramate extended-release capsules) for chronic weight management in adolescents aged 12 years and older who are obese. Qsymia was originally approved in 2012 for adults who are obese.
The approval was based on data from a 56-week, placebo-controlled study of 223 people aged 12 to less than 17 years old with a body mass index (BMI) at the 95th percentile or greater. Patients taking Qsymia 7.5 mg/46 mg and Qsymia 15 mg/92 mg lost, on average, 4.8% and 7.1% of their BMI, respectively, while individuals receiving the placebo gained an average of 3.3% of their BMI.
Adolescent obesity has increased over the last 50 years with 21% (1 in 5) of U.S. adolescents now considered obese. Obesity in pediatric patients is a serious condition and may adversely impact health by increasing the risk of many diseases, such as heart disease. Many obese children are likely to become obese adults.
Because of the increased risk for birth defects (cleft lip and cleft palate) with fetal exposure to Qsymia during pregnancy, Qsymia is only available through a Risk Evaluation and Mitigation Strategy (REMS) program. Qsymia is only available through certified pharmacies.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 1st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
